BZYR (Burzynski Research Institute) Debt-to-Equity: 0.00 (As of Nov. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Burzynski Research Institute Debt-to-Equity?

Burzynski Research Institute BZYR Debt-to-Equity is 0.00 as of Nov. 2025. Among 968 Biotechnology companies, Burzynski Research Institute ranks worse than 103305.68% on this metric.

Burzynski Research Institute's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Nov. 2025 was $0.00 Mil. Burzynski Research Institute's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Nov. 2025 was $0.00 Mil. Burzynski Research Institute's Total Stockholders Equity for the quarter that ended in Nov. 2025 was $-0.07 Mil. Burzynski Research Institute's debt to equity for the quarter that ended in Nov. 2025 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Burzynski Research Institute's Debt-to-Equity or its related term are showing as below:

BZYR's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.16
* Ranked among companies with meaningful Debt-to-Equity only.

Burzynski Research Institute  (OTCPK:BZYR) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Burzynski Research Institute Debt-to-Equity Related Terms

Burzynski Research Institute Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Burzynski Research Institute's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Burzynski Research Institute Debt-to-Equity Chart

Burzynski Research Institute Annual Data
Trend Feb16 Feb17 Feb18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24 Feb25
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Burzynski Research Institute Quarterly Data
Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BZYR vs AGTX, EMMA, ATXI: Debt-to-Equity Comparison

For the Biotechnology subindustry, Burzynski Research Institute's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Burzynski Research Institute Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Burzynski Research Institute's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Burzynski Research Institute's Debt-to-Equity falls into.


Burzynski Research Institute Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Burzynski Research Institute's Debt to Equity Ratio for the fiscal year that ended in Feb. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / -0.042
=0.00

Burzynski Research Institute's Debt to Equity Ratio for the quarter that ended in Nov. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / -0.067
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of 0.00 mean?
Burzynski Research Institute (BZYR) has a Debt-to-Equity of 0.00 as of Nov. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Burzynski Research Institute and its competitors. According to the industry distribution chart, Burzynski Research Institute ranks #999999 out of 968 companies in the Biotechnology industry.
Is Burzynski Research Institute's Debt-to-Equity too high?
Burzynski Research Institute's current Debt-to-Equity is 0.00. Based on the distribution chart, Burzynski Research Institute ranks #999999 out of 968 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Burzynski Research Institute's Debt-to-Equity compare to AGTX and EMMA?
According to the Biotechnology industry distribution chart, Burzynski Research Institute ranks #999999 out of 968 companies for Debt-to-Equity. This places Burzynski Research Institute in the lower half of its industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 968 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Burzynski Research Institute and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Burzynski Research Institute's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Burzynski Research Institute stock overvalued right now?
Burzynski Research Institute (BZYR) has a current Debt-to-Equity of 0.00. The current Debt-to-Equity is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Burzynski Research Institute (BZYR), the current Debt-to-Equity is 0.00 as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Burzynski Research Institute Business Description

Address 9432 Katy Freeway, Houston, TX, USA, 77055
Burzynski Research Institute Inc operates as a research and development facility of Antineoplaston drugs currently being tested for the use in the treatment of cancer, and provides consulting services.